We are continuously adding more assays and models to our portfolio while also actively improving our current models. In collaboration with Cellevate AB we have further developed our ex vivo models of inflammation. Cellevate is an innovative biotech company using nanomaterials to develop the next generation 3D cell culture systems. By using Cellevates 3D cell culture scaffolds we have gained increased stability and predictability in our immune cell stimulation assays (murine and human). These models provide a versatile tool for basic understanding and evaluation of effects on immune cell activation and can be used for tailored studies on project specific subsets, targets or biomarkers. Traditionally, in vitro models have suffered from major limitations in predictability due to altererd morphology of cells during culture. By mimicking the structures in which cells resides in vivo during evaluation of potential new therapies the likelihood of selecting biologically relevant substances for in vivo experiments can be increased.
We are now providing our assays for immune cell activation ex vivo with 3D cell culture setup. Contact us at firstname.lastname@example.org for more information on how we can tailor these models to suit your specific project. For more information on Cellevates 3D cell culture stystems contact email@example.com.
Redoxis AB has signed an agreement with Taconic Biosciences, Inc for service of characterization of cellular composition of Taconic’s humanized immune system mice. This contract covers a recurrent service spanning over three years.
“We are very excited about the collaboration with Taconic, which will beneficially impact Redoxis by adding value and financial stability to our in vitro service platform” says Malin Hultqvist Hopkins, CEO, Redoxis.
For additional information please contact:
As of beginning of March, Redoxis is now a registered trademark in the US. Redoxis has previously been a registered trademark in Sweden and European Union and was lately approved for registration by the United States Patent and Trademark Office.
“The registration of the trademark Redoxis in the US is an important step of our internationalisation strategy to increase Redoxis recognition within the American market for CRO services” says Peter Olofsson, founder and board member of Redoxis.
The current Covid-19 situation is clearly affecting all of us but Redoxis CRO services are still fully operational. In addition to our already validated and standardized animal models we routinely implement and set up new models on demand. With a fully equipped lab, we can also set up in vitro assays on demand, including flow cytometry, ELISA, Luminex and qPCR.
Contact us for a discussion on who we can facilitate and assist your preclinical development in inflammation and autoimmunity.
Successful translation of in vitro results to in vivo proof of concept data is essential in early drug development. Traditionally, in vitro models have had major limitations in predictability but the use of 3D cell cultures, mimicking structures in which cells resides in vivo, increased translatability can be achieved. We are now, in collaboration with Cellevate, looking for a student interested to take on a master project where new 3D ex vivo models for skin inflammatory diseases will be validated and evaluated for use in early drug discovery. The project will involve both practical lab work as well as in-depth theory and engineering of 3D nanofiber networks.